Insider · CIK 0001724097

ABERNETHY MATT

Reports to the SEC for 2 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001724097

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-14	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Financial Officer	SSale	−2,311 sh	$157.20	−$363K	42,808
2026-09-11	NBIXNEUROCRINE BIOSCIENCES INCA Award	Chief Financial Officer	AAward	+5,020 sh	—	—	47,828
2026-09-11	NBIXNEUROCRINE BIOSCIENCES INCF Tax Payment	Chief Financial Officer	FTax Payment	−2,709 sh	$156.22	−$423K	45,119
2026-06-12	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)A Award	Director	AAward	+87.9K sh	—	—	87,900
2026-03-04	NBIXNEUROCRINE BIOSCIENCES INCG Gift	Chief Financial Officer	GGift	−2,249 sh	—	—	42,808
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INCF Tax Payment	Chief Financial Officer	FTax Payment	−5,378 sh	$124.12	−$668K	44,881
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INCA Award	Chief Financial Officer	AAward	+9,968 sh	—	—	50,259
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INCF Tax Payment	Chief Financial Officer	FTax Payment	−1,385 sh	$124.12	−$172K	40,291
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,566 sh	—	—	41,676
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,241 sh	—	—	40,320
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INCF Tax Payment	Chief Financial Officer	FTax Payment	−1,210 sh	$124.12	−$150K	39,110
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitA Award	Chief Financial Officer	AAward	+7,735 sh	—	—	7,735
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INC · Stock OptionA Award	Chief Financial Officer	AAward	+44.1K sh	—	—	44,095
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,566 sh	—	—	2,566
2026-02-13	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,241 sh	—	—	4,484
2026-02-12	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,133 sh	—	—	39,230
2026-02-12	NBIXNEUROCRINE BIOSCIENCES INCF Tax Payment	Chief Financial Officer	FTax Payment	−1,151 sh	$123.10	−$142K	38,079
2026-02-12	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,133 sh	—	—	6,401
2026-01-31	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,437 sh	—	—	0
2026-01-31	NBIXNEUROCRINE BIOSCIENCES INCF Tax Payment	Chief Financial Officer	FTax Payment	−1,368 sh	$136.06	−$186K	37,097
2026-01-31	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,437 sh	—	—	38,465
2025-05-29	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)A Award	Director	AAward	+110K sh	—	—	110,000
2025-02-13	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Financial Officer	SSale	−1,206 sh	$116.87	−$141K	35,810
2025-02-13	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,566 sh	—	—	36,127
2025-02-13	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Financial Officer	SSale	−1,352 sh	$116.85	−$158K	34,775
2025-02-13	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,241 sh	—	—	37,016
2025-02-13	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,566 sh	—	—	5,132
2025-02-13	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,241 sh	—	—	6,725
2025-02-12	NBIXNEUROCRINE BIOSCIENCES INC · Stock OptionA Award	Chief Financial Officer	AAward	+45.5K sh	—	—	45,538
2025-02-12	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitA Award	Chief Financial Officer	AAward	+8,534 sh	—	—	8,534
2025-02-10	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Financial Officer	SSale	−980 sh	$118.27	−$116K	33,561
2025-02-08	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+1,860 sh	—	—	34,541
2025-02-08	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−1,860 sh	—	—	0
2025-01-31	NBIXNEUROCRINE BIOSCIENCES INC · Restricted Stock UnitM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,436 sh	—	—	2,437
2025-01-31	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Financial Officer	SSale	−1,283 sh	$152.87	−$196K	32,681
2025-01-31	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,436 sh	—	—	33,964
2024-08-13	NBIXNEUROCRINE BIOSCIENCES INC · Non-Qualified Stock OptionM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−14.1K sh	—	—	0
2024-08-13	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+14.1K sh	$73.60	+$1.04M	45,628
2024-08-13	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Financial Officer	SSale	−14.1K sh	$150.38	−$2.12M	31,528
2024-07-16	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+900 sh	$73.60	+$66.2K	32,428
2024-07-16	NBIXNEUROCRINE BIOSCIENCES INC · Non-Qualified Stock OptionM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−900 sh	—	—	14,100
2024-07-16	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Financial Officer	SSale	−900 sh	$150.04	−$135K	31,528
2024-05-15	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+15K sh	$73.60	+$1.1M	46,528
2024-05-15	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Financial Officer	SSale	−15K sh	$140.24	−$2.1M	31,528
2024-05-15	NBIXNEUROCRINE BIOSCIENCES INC · Non-Qualified Stock OptionM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−15K sh	$73.60	−$1.1M	15,000
2024-05-14	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Financial Officer	SSale	−15K sh	$135.66	−$2.03M	31,528
2024-05-14	NBIXNEUROCRINE BIOSCIENCES INC · Non-Qualified Stock OptionM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−15K sh	$73.60	−$1.1M	30,000
2024-05-14	NBIXNEUROCRINE BIOSCIENCES INCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+15K sh	$73.60	+$1.1M	46,528
2024-02-13	NBIXNEUROCRINE BIOSCIENCES INC · Stock OptionA Award	Chief Financial Officer	AAward	+45.1K sh	—	—	45,058
2024-02-13	NBIXNEUROCRINE BIOSCIENCES INCS Sale	Chief Financial Officer	SSale	−1,352 sh	$132.85	−$180K	31,528

Recent filings

Accepted (ET)
Sep 154
ABERNETHY MATT0001724097-26-000010
SEC(opens sec.gov)
Jun 154
ABERNETHY MATT0001193125-26-271074
SEC(opens sec.gov)
Mar 54
ABERNETHY MATT0001724097-26-000007
SEC(opens sec.gov)
Feb 174
ABERNETHY MATT0001724097-26-000005
SEC(opens sec.gov)
Feb 34
ABERNETHY MATT0001724097-26-000003
SEC(opens sec.gov)

Companies

Address

6027 EDGEWOOD BEND CT.

SAN DIEGO, CA, 92130